1460926645-8944b426-0069-41f7-bbb1-364902c9b79d

1. A computer implemented method for system management, the computer implemented method comprising:
responsive to receiving a set of application tasks from a registration module during application run-time, registering the set of application tasks and a set of system management tasks to form a schedule of tasks based on a set of policies stored in a policy database,
wherein the set of policies comprises a type of a task, an importance of the task, and a probable time to complete the task,
wherein the set of application tasks comprises a set of one or more sub-processes of an application to perform in order to execute the application, and
wherein the set of system management tasks comprises a set of one or more tasks performed to maintain and manage system resources and facilitate operation of an operating system and the application;
performing a feasibility analysis on the schedule of tasks to evaluate the schedule of tasks to:

determine if the schedule of tasks can execute within constraints specified in the set of policies, and
determine an order to execute the schedule of tasks by, identifying periods of decreased system activity, wherein the periods of decreased activity comprises of blocks of time within the schedule of tasks where no application task is currently scheduled to execute, within which to order the schedule of tasks to execute a system management task within the set of system management tasks;

computer usable code for performing a feasibility analysis on the schedule of tasks to evaluate the schedule of tasks to:
determine if the schedule of tasks can execute within constraints specified in the set of policies, and
determine an order to execute the schedule of tasks by, identifying periods of decreased system activity, wherein the periods of decreased activity comprises of blocks of time within the schedule of tasks where no application task is currently scheduled to execute, within which to order the schedule of tasks to execute a system management task within the set of system management tasks;

generating a prioritized schedule of tasks to execute in order based on the feasibility analysis that identifies an order for completing each task in the prioritized schedule of tasks;
wherein priorities are assigned to each task in the prioritized schedule of tasks according to a scheduling policy; and
wherein the set of system management tasks further comprises at least one of garbage collection and compiling.
7. The computer program product of claim 6, further comprising:
computer usable program code for preempting the scheduled task having a lower priority in response to receiving an asynchronous event task with a higher priority than a scheduled task on the prioritized schedule of tasks.
8. The computer program product of claim 6, wherein the set of application tasks and the set of system management tasks are scheduled during the generation of the prioritized schedule of tasks according to a set of execution details, and wherein the execution details comprise a period of a task in the schedule of tasks and a duration of the task in the schedule of tasks.
9. The computer program product of claim 6, wherein the prioritized schedule of tasks further identifies a period of execution for completing each task in the prioritized schedule of tasks.
10. The computer program product of claim 6, further comprising:
presenting results of the feasibility analysis to a user.
11. An apparatus comprising:
a processor unit comprised of at least one processor connected to a memory storing program code, wherein the processor unit executes the program code comprising:
a registration module, wherein the registration module registers a set of application tasks during application run-time; and
an active scheduler, wherein the active scheduler generates a prioritized schedule of tasks from the set of application tasks and a set of system management tasks, the active scheduler,
performing a feasibility analysis on a schedule of tasks created from the set of application tasks and the set of system management tasks based on a set of policies stored in a policy database to determine if the schedule of tasks can execute within constraints specified in the set of policies stored in the database and to determine an order to execute the schedule of tasks in,
identifying periods of decreased system activity, wherein the periods of decreased activity comprise blocks of time within the schedule of tasks where no application task is scheduled to execute, within which the active scheduler orders the schedule to execute a system management task within the set of system management tasks, and
generating a prioritized schedule of tasks to execute in order based on the feasibility analysis that identifies an order for completing each task in the prioritized schedule of tasks;
wherein priorities are assigned to each task in the prioritized schedule of tasks according to a scheduling policy; and
wherein the set of system management tasks comprises at least one of garbage collection and compiling.
12. The apparatus of claim 11, further comprising:
an asynchronous event handler, wherein the asynchronous event handler registers a set of asynchronous event tasks.
13. The apparatus of claim 11, further comprising:
a scheduling policy database, wherein the scheduling policy database stores a set of rules for assigning priorities to tasks in the prioritized schedule of tasks.
14. An apparatus for managing system resources, the apparatus comprising:
a bus system,
memory connected to the bus system, wherein the memory includes computer usable program code; and
a processing unit connected to the bus system, wherein the processing unit executes the computer usable program code to register a set of application tasks during application run-time and a set of system management tasks to form a schedule based on a set of policies stored in a policy database,
wherein the set of policies comprises a type of a task, an importance of the task, and a probable time to complete the task,
wherein the set of application tasks comprises a set of one or more sub-processes of an application to perform in order to execute the application, and
wherein the set of system management tasks comprises a set of one or more tasks performed to maintain and manage system resources and facilitate operation of an operating system and the application; and

perform a feasibility analysis on the schedule of tasks to determine if the schedule of tasks can execute within constraints specified in the set of policies stored in the database and to:
determine an order to execute the schedule of tasks by, identifying periods of decreased system activity, wherein the periods of decreased activity comprise blocks of time within the schedule of tasks where no application task is scheduled to execute, within which the active scheduler orders the schedule to execute a system management task within the set of system management tasks; and
generate a prioritized schedule of tasks to execute in order based on the feasibility analysis that identifies an order for completing each task in the prioritized schedule of tasks;

wherein priorities are assigned to each task in the prioritized schedule of tasks according to a scheduling policy; and
wherein the set of system management tasks further comprises at least one of garbage collection and compiling.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula I\u2032:
or a pharmaceutically acceptable salt thereof, wherein:
each is independently a double or single bond with the proviso that two adjacent double bonds do not exist;
n=1 or 2;
m=0, 1
each of X1\u2032, X2\u2032, X3\u2032 and X4\u2032 is independently selected from N,N(R2\u2032), O, S, and C(R2\u2032), as valency permits, wherein at least one of X1\u2032, X2\u2032, X3\u2032 and X4\u2032 is either N or N(R2\u2032);
A\u2032 is phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein A\u2032 is optionally substituted with one or more R1\u2032 substituents;
each R1\u2032 is independently selected from the group of halogen (F, Cl, Br, I), \u2014NO2, \u2014CN, \u2014ORa, \u2014SRa, \u2014N(Ra)2, \u2014N3, or -L1-R;
each R2\u2032 is independently selected from \u2014H,
halogen (F, Cl, Br, I), \u2014NO2, \u2014CN, \u2014ORa, \u2014SRa, \u2014N(Ra)2, \u2014N3, or -L1-R;
each WG\u2032 is independently selected from the group consisting of \u2014H, \u2014F, \u2014CF3, \u2014NO2, \u2014CN, \u2014C(O)R3\u2032, \u2014C(O)OR3\u2032, \u2014S(O)R3\u2032, \u2014SO2R3\u2032, \u2014C(O)N(R3\u2032)2 and \u2014C(NOR3\u2032)R4\u2032;
each R3\u2032 and R4\u2032 is independently -L1-R;
each R is independently optionally substituted C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, haloalkyl, phenyl, a 3-7 membered saturated or partially unsaturated cycloalkyl ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring, a 4-7-membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:
two R on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulphur L1 is a covalent bond or an optionally substituted bivalent C1-6 hydrocarbon chain, wherein one or more methylene units of L1 is optionally and independently replaced by -Cy-, \u2014O\u2014, \u2014S\u2014, \u2014N(Ra)\u2014, \u2014C(O)\u2014, \u2014C(O)N(Ra)\u2014, \u2014N(Ra)C(O)N(Ra)\u2014, \u2014N(Ra)C(O)\u2014, \u2014N(Ra)C(O)O\u2014, \u2014OC(O)N(Ra)\u2014, \u2014S(O)\u2014, \u2014S(O)2\u2014, \u2014S(O)2N(Ra)\u2014, \u2014N(Ra)S(O)2\u2014, \u2014OC(O)\u2014 or \u2014C(O)O\u2014;
-Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7-membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
each Ra is independently \u2014H, \u2014R or \u2014C(O)R;

provided that the compound is not one disclosed in Van Neck et al. Bioorgan. Med. Chem. 16 (2008) 9487-9497.
2. The compound according to claim 1, wherein the compound is of formula II\u2032:
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, wherein A\u2032 is phenyl optionally substituted with one or more R1\u2032 substituent.
4. The compound according to claim 3, wherein A\u2032 is phenyl substituted with R1 at the meta-position and each WG\u2032 is independently \u2014CO2Et, \u2014CO2CH(CH3)2, \u2014CO2C(CH3)3 or \u2014CO2Ph.
5. The compound according to claim 1, wherein the compound has the formula III\u2032 or IV\u2032:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1, wherein WG\u2032 is selected from:
\u2014CO2Et, \u2014CO2CH(CH3)2, \u2014CO2C(CH3)3, CONH-phenyl,
7. The compound according to claim 4, wherein R1 is \u2014Cl.
8. The compound according to claim 7, wherein WG is CO2CH(CH3)2.
9. The compound according to claim 2, wherein one WG\u2032 is hydrogen and the other WG\u2032 is \u2014CO2Et, \u2014CO2CH(CH3)2, \u2014CO2C(CH3)3, CONH-phenyl,
10. The compound according to claim 1, wherein the compound has the formula V\u2032 or VI\u2032:
or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 1 selected from the group consisting of:
Example
Structure
Name
1
(Z)-3-3-(3-Chloro-phenyl)- 1,2,4-triazol-1-yl-acrylic acid isopropyl ester

2
(E)-3-3-(3-Chloro-phenyl)- 1,2,4-triazol-1-yl-acrylic acid isopropyl ester

3
(Z)-isopropyl 3-(3-(4- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

4
(Z)-isopropyl 3-(3-(2- fluoro-1,1\u2032-biphenyl-4-yl)- 1H-1,2,4-triazol-1- yl)acrylate

5
(Z)-isopropyl 3-(3-(3- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

6
(Z)-isopropyl 3-(3-(3,4- dichlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

7
(Z)-tetrahydrofuran-3-yl 3- (3-(3-chlorophenyl)-1H- 1,2,4-triazol-1-yl)acrylate

8
(Z)-cyclobutyl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

9
(Z)-pyridin-2-ylmethyl 3-(3- (3-chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

10
(Z)-isopropyl 3-(3-(5- chIoro-2-methoxyphenyl)- 1H-1,2,4-triazol-1- yl)acrylate

11
(Z)-isopropyl 3-(3-(3- chloro-5-methoxyphenyl)- 1H-1,2,4-triazol-1- yl)acrylate

12
(Z)-isopropyl 3-(3-(3- chloro-5- isopropoxyphenyl)-1H- 1,2,4-triazol-1-yl)acrylate

13
(Z)-3-3-(3,5-Dichloro- phenyl)-1,2,4triazol-1-yl- acrylic acid ethyl ester

14
(Z)-isopropyl 3-(3-(3- chloro-4-methoxyphenyl)- 1H-1,2,4-triazol-1- yl)acrylate

15
(Z)-3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1-yl)-N- cyclopentylacrylamide

16
(Z)-5-oxotetrahydrofuran yl 3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1- yl)acrylate

17
(Z)-isopropyl 3-(3-(4-(4- chlorophenoxy)phenyl)-1H- 1,2,4-triazol-l-yl)acrylate

18
(Z)-isopropyl 3-(3-(3- chloro-5- (methylamino)phenyl)-1H- 1,2,4-triazol-1-yl)acrylate

19
(Z)-azetidin-3-yl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

20
(Z)-isopropyl 3-(3-(3,5- dimethoxyphenyl)-1H- 1,2,4-triazol-1-yl)acrylate

21
(Z)-tert-butyl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

22
(Z)-cyclopentyl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

23
(Z)-cyclohexyl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

24
(Z)-isopropyl 3-(3-(5- chlorothiophen-3-yl)-1H- 1,2,4-triazol-1-yl)acrylate

25
(Z)-pyrrolidin-2-ylmethyl 3- (3-(3-chlorophenyl)-1H- 1,2,4-triazol-1-yl)acrylate

26
(Z)-isopropyl 3-(3-(3- methoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

27
(Z)-isopropyl 3-(3-(3- chloro-5-(4- chlorophenoxy)phenyl)-1H- 1,2,4-triazol-1-yl)acrylate

28
(Z)-isopropyl 3-(3-(2,6- dichloropyridin-4-yl)-1H- 1,2,4-triazol-1-yl)acrylate

29
(Z)-3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1- yl)acrylonitrile

30
(Z)-3-(3-chlorophenyl)-1- (2-(methylsulfonyl)vinyl)- 1H-1,2,4-triazole

31
(Z)-ethyl 3-(3-(3-chloro-5- methoxyphenyl)-1H-1,2,4- triazol-1-yl)acrylate

32
(Z)-methyl 3-(3-(3-chloro- 5-methoxyphenyl)-1H- 1,2,4-triazol-1-yl)acrylate

33
(Z)-methyl 3-(3-(3-chloro- 5-methoxyphenyl)-1H- 1,2,4-triazol-1-yl)acrylate

34
(Z)-(1H-imidazol-5- yl)methyl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

35
(Z)-isopropyl 3-(3-(5- chloropyridin-3-yl)-1H- 1,2,4-triazol-1-yl)acrylate

36
(Z)-1-(azetidin-1-yl)-3-(3- (3-chlorophenyl)-1H-1,2,4- triazol-1-yl)prop-2-en-1-one

37
(Z)-isopropyl 3-(3-(m- tolyl)-1H-1,2,4-triazol-1- yl)acrylate

38
(Z)-isopropyl 3-(3-(3- chloro-5- (trifluoromethoxy)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

39
(Z)-isopropyl 3-(3-(2- chloro-6-isopropoxypyridin- 4-yl)-1H-1,2,4-triazol-1- yl)acrylate

40
(Z)-isopropyl 4-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)but-2-enoate

41
(E)-isopropyl 4-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)but-2-enoate

42
(E)-3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1- yl)acrylonitrile

43
(Z)-tetrahydro-2H-pyran-4- yl 3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1- yl)acrylate

44
(Z)-isopropyl 3-(3-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

45
(Z)-isopropyl 3-(3-(3-(2- (dimethylamino)ethoxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

46
(E)-isopropyl 3-(3-(3-(2- (dimethylamino)ethoxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

47
(Z)-3-(3-chlorophenyl)-1- (3,3,3-trifluoroprop-1-en-1- yl)-1H-1,2,4-triazole

48
(Z)-azetidin-3-yl 3-(3-(3- methoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

49
(Z)-oxetan-3-yl 3-(3-(3- chlorophcnyl)-1H-1,2,4- triazol-1-yl)acrylate

50
(Z)-isopropyl 3-(3-(3- cyano-5-isopropoxyphenyl)- 1H-1,2,4-triazol-1- yl)acrylate

51
(Z)-azetidin-3-yl 3-(3-(2,6- dichloropyridin-4-yl)-1H- 1,2,4-triazol-1-yl)acrylate

52
(Z)-isopropyl 3-(3-(2- chloro-6- (isopropylamino)pyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

53
(Z)-3-(3-(3-isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylonitrile

54
(E)-azetidin-3-yl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

55
(E)-isopropyl 3-(3-(3-(2- (pyrrolidin-1-yl)ethoxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

56
(Z)-isopropyl 3-(3-(2- chlorothiazol-4-yl)-1H- 1,2,4-triazol-1-yl)acrylate

57
(Z)-isopropyl 3-(3-(2- bromothiazol-4-yl)-1H- 1,2,4-triazol-1-yl)acrylate

58
(Z)-isopropyl 3-(3-(3-(2- (pyrrolidin-1-yl)ethoxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

59
(Z)-isopropyl 3-(3-(3- chloro-5-(2- methoxyethoxy)phenyl)-1H- 1,2,4-triazol-1-yl)acrylate

60
(Z)-isopropyl 3-(3-(2- isopropoxy-6- (trifluoromethyl)pyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

61
(Z)-isopropyl 3-(3-(2- chloro-6-methoxypyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

62
(E)-isopropyl 3-(3-(1-((Z)- 3-isopropoxy-3-oxoprop-1- en-1-yl)-1H-1,2,4-triazol-3- yl)-5- (trifluoromethyl)phenoxy) acrylate

63
(Z)-pyridin-2-ylmethyl 3-(3- (2-isopropoxy-6- (trifluoromethyl)pyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

64
(Z)-pyridin-2-ylmethyl 3-(3- (3-isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

65
(Z)-isopropyl3-(3-(2- (isopropylambo)-6- (trifluoromethyl)pyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

66
(Z)-isopropyl 3-(3-(2- (cyclobutylamino)-6- (trifluoromethyl)pyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

67
(Z)-isopropyl 3-(3-(3- (methylsulfonyl)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

68
(Z)-isopropyl 3-(3-(3- (isopropylamino)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

69
(Z)-isopropyl 3-(3-(3- (cyclobutylamino)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

70
(Z)-isopropyl 3-(3-(3- fluoro-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

71
(Z)-1-(3,3-difluoroazetidin- 1-yl)-3-(3-(3-methoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1-yl)prop- 2-en-1-one

72
(Z)-3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1-yl)-1- (3,3-difluoroazetidin-1- yl)prop-2-en-1-one

73
(Z)-1-(3,3-difluoroazetidin- 1-yl)-3-(3-(3-isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1-yl)prop- 2-en-1-one

74
(Z)-isopropyl 3-(3-(3- hydroxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

75
(Z)-isopropyl 3-(3-(3,5- bis(trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

76
(Z)-3-3-(3-Chloro-phenyl)- 1,2,4-triazol-1-yl-acrylic acid ethyl ester

77
(E)-3-3-(3-Chloro-phenyl)- 1,2,4-triazol-1-yl-acrylic acid ethyl ester

78
(E)-3-3-(3-Chloro-phenyl)- 1,2,4-triazol-1-yl-acrylic acid tert-butyl ester

79
(Z)-3-3-(3-Chloro-phenyl)- 1,2,4triazol-1-yl-acrylic acid phenyl ester

80
(Z)-3-5-(3-Chloro-phenyl)- 1H-1,2,4triazol-3-yl- acrylic acid isopropyl ester

81
3-3-(2-Amino-5-chloro- phenyl)-1,2,4triazol-1-yl- acrylic acid isopropyl ester

82
3-3-(3-Chloro-5-fluoro- phenyl)-1,2,4triazol-1-yl- acrylic acid ethyl ester

83
3-3-(3-Fluoro-phenyl)- 1,2,4triazol-1-yl-acrylic acid ethyl ester

84
(Z)-isopropyl 3-(5-(3,5- dichlorophenyl)-1H-1,2,4- triazol-3-yl)acrylate

85
(Z)-3-(5-(3-chlorophenyl)- 4H-1,2,4-triazol-3-yl)-N- phenylacrylamide

86
(Z)-3-(5-(3-chlorophenyl)- 4H-1,2,4-triazol-3-yl)-N- methyl-N-phenylacrylamide

87
(Z)-isopropyl 3-(5-(3- fluorophenyl)-4H-1,2,4- triazol-3-yl)acrylate

88
(Z)-ethyl 3-(3-(3,5- dichlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

89
(Z)-ethyl 3-(3-(3,5- difluorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

90
(E)-tert-butyl (4-(3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1- yl)acrylamido)phenyl) carbamate

92
(E)-3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1-yl)-N-(4- methoxyphenyl)acrylamide

93
(E)-N-(3 Chloro-phenyl)-3-3-(3- chloro-phenyl)-1,2,4- triazol-1-yl-acryl amide

94
(E)-N-(4-Amino-phenyl)-3- 3-(3-chloro-phenyl)- 1,2,4-triazol-1-yl-acryl amide

95
3-5-(3-Chloro-phenyl)-1H- 1,2,4triazol-3-yl-N- isopropyl-N-methyl- acrylamide

96
(Z)-isopropyl 3-(3-(5- chloro-2-(1H-imidazol-1- yl)phenyl)-1H-1,2,4-triazol- 1-yl)acrylate

97
(Z)-isopropyl 3-(3-(6- fluoro-1H-indol-4-yl)-1H- 1,2,4-triazol-1-yl)acrylate

98
(Z)-isopropyl 3-(3-(4- chloronaphthalen-2-yl)-1H- 1,2,4-triazol-1-yl)acrylate

99
(Z)-isopropyl 3-(3-(3- (isopropylamino)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

100
(Z)-isopropyl 3-(3-(3-((4- chlorophenyl)amino)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

101
(Z)-isopropyl 3-(3-(3- (pyrimidin-5-yloxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

102
(1Z,2Z)-isopropyl N-cyano- 3-(3-(3-methoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylimidate

103
(E)-isopropyl 2-fluoro-3-(3- (3-methoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

104
(Z)-isopropyl 3-(3-(2- chloro-6-((4- chlorobenzyl)oxy)pyridin-4- yl)-1H-1,2,4-triazol-1- yl)acrylate

105
(Z)-1-(2,2,2- trifluoroethyl)azetidin-3-yl 3-(3-(3-methoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

106
(Z)-isopropyl 3-(3-(3-((2- fluoropropan-2-yl)oxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

107
(Z)-isopropyl 3-(3-(3- (trifluoromethoxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

108
(S,Z)-1-(pyridin-2-yl)ethyl 3-(3-(3-isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

109
(Z)-(lH-imidazol-2- yl)methyl 3-(3-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

110
(Z)-(1,3,4-thiadiazol-2- yl)methyl 3-(3-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

111
(Z)-isopropyl 3-(3-(3- carbamoyl-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

112
(Z)-isopropyl 3-(3-(3- cyano-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

113
(Z)-isopropyl 3-(3-(3- (methylcarbamoyl)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

114
(Z)-isopropyl 3-(3-(3- (piperazine-1-carbonyl)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

115
(Z)-isopropyl 3-(3-(3- (pyrrolidine-1-carbonyl)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

116
(Z)-2-fluoropropan-2-yl 3- (3-(3-isopropoxy-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

117
(Z)-isopropyl 3-(3-(4- chloropyridin-2-yl)-1H- 1,2,4-triazol-1-yl)acrylate

118
(Z)-isopropyl 3-(3-(3- (difluoromethyl)-5- isopropoxyphenyl)-1H- 1,2,4-triazol-1-yl)acrylate

119
(Z)-3-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1-yl)-N- fluoro-N- isopropylacrylamide

120
(Z)-isopropyl 3-(3-(3- (pyridin-2-yloxy)-5- (trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1- yl)acrylate

121
(Z)-1-(3-(3-chlorophenyl)- 1H-1,2,4-triazol-1-yl)-4,4- dimethylpent-1-en-3-one

122
(Z)-(4H-1,2,4-triazol-3- yl)methyl 3-(3-(3- chlorophenyl)-1H-1,2,4- triazol-1-yl)acrylate

123
(Z)-isopropyl 3-(4-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-imidazol-1-yl)acrylate

124
(Z)-isopropyl 3-(2-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-imidazol-4-yl)acrylate

125
(Z)-isopropyl 3-(5-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-pyrrol-3-yl)acrylate

126
(Z)-isopropyl 3-(3-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-pyrrol-1-yl)acrylate

127
(Z)-isopropyl 3-(3-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 1H-pyrazol-1-yl)acrylate

128
(Z)-isopropyl 3-(5-(3- isopropoxy-5- (trifluoromethyl)phenyl)- 2H-tetrazol-2-yl)acrylate
or a pharmaceutically acceptable salt thereof.
12. A composition comprising a compound of formula I\u2032, and a pharmaceutically acceptable carrier, adjuvant, or vehicle:
or a pharmaceutically acceptable salt thereof, wherein:
each is independently a double or single bond with the proviso that two adjacent double bonds do not exist;
n=1 or 2;
m=0, 1
each of X1\u2032, X2\u2032, X3\u2032 and X4\u2032 is independently selected from N,N(R2\u2032), O, S, and C(R2\u2032), as valency permits, wherein at least one of X1\u2032, X2\u2032, X3\u2032 and X4\u2032 is either N or N(R2\u2032);
A\u2032 is phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein A\u2032 is optionally substituted with one or more R1\u2032 substituents;
each R1\u2032 is independently selected from the group of halogen (F, Cl, Br, I), \u2014NO2, \u2014CN, \u2014ORa, \u2014N(Ra)2, \u2014N3, or -L1-R;
each R2\u2032 is independently selected from \u2014H,
halogen (F, Cl, Br, I), \u2014NO2, \u2014CN, \u2014ORa, \u2014SRa, \u2014N(Ra)2, \u2014N3, or -L1-R;
each WG\u2032 is independently selected from the group consisting of \u2014H, \u2014F, \u2014CF3, \u2014NO2, \u2014CN, \u2014C(O)R3\u2032, \u2014C(O)OR3\u2032, \u2014S(O)R3\u2032, \u2014SO2R3\u2032, \u2014C(O)N(R3\u2032)2 and \u2014C(NOR3\u2032)R4\u2032;
each R3\u2032 and R4\u2032 is independently -L1-R;
each R is independently optionally substituted C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, haloalkyl, phenyl, a 3-7 membered saturated or partially unsaturated cycloalkyl ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring, a 4-7-membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:
two R on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulphur L1 is a covalent bond or an optionally substituted bivalent C1-6 hydrocarbon chain, wherein one or more methylene units of L1 is optionally and independently replaced by -Cy-, \u2014O\u2014, \u2014S\u2014, \u2014N(Ra)\u2014, \u2014C(O)\u2014, \u2014C(S)\u2014, \u2014C(O)N(Ra)\u2014, \u2014N(Ra)C(O)N(Ra)\u2014, \u2014N(Ra)C(O)\u2014, \u2014N(Ra)C(O)O\u2014, \u2014OC(O)N(Ra)\u2014, \u2014S(O)\u2014, \u2014S(O)2\u2014, \u2014S(O)2N(Ra)\u2014, \u2014N(Ra)S(O)2\u2014, \u2014OC(O)\u2014 or \u2014C(O)O\u2014;
-Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7-membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
each Ra is independently \u2014H, \u2014R or \u2014C(O)R.
13. A method for modulating CRM1 comprising contacting CRM1 with a therapeutically effective amount of composition according to claim 12.
14. A method for treating, modulating, andor preventing a disorder associated with CRM1 comprising administering a therapeutically effective amount of a composition according to claim 12.
15. The method according to claim 14, wherein the said disorder is chosen from cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and viral infections (both acute and chronic).